Drug maker-stymie generic competition

Question

Drug maker want to stymie generic competition. Elucidate this statement.

Answer 1

The drug maker has been willing to hind the stymie generic competition of their drug through being keeping a patent on the drug through the use of Hatch-Waxman Act enacted in the year 1984 that means that the patent has been placed on the drug for preventing anybody else to make, use as well as to sell patented invention. This has been granted through the government or the regional authority. The patent term lasts for twenty years that means at that point of time, patent holder are having the monopoly on invention such as the medicine as well as may charge highest price that market may bear.

However generic drug makers are regularly challenging the drug patents by the time they have been scheduled for the expiration. It has been a billion dollar business as well as nobody has been willing towards sharing in profits till they need to provide rights for making the drugs. To keep all the others away by our drug as well as keeping patents as long as it is feasible in making much more money for company (Association, 2011).

This was proven towards being a case for HIV medicines to develop countries. If HIV medicine initially came out patent has prevented lot of people from using that as that had been very costly, after generic versions of medicines are present, prices fell on the average about forty to eighty percent. For instance the price of traditional, 1st line HIV medicines had been fell from much more than United States $10,000 for one person every year in the year 2000 towards under $70 now a days.